Intensity Therapeutics(US:INTS)2025-10-31 14:00Summary of Intensity Therapeutics Conference Call Company Overview - Company: Intensity Therapeutics, Inc. (NasdaqCM: INTS) - Focus: Development of INT230-6, a novel intratumoral chemotherapy drug aimed at treating solid tumors Key Industry Insights - Industry: Oncology, specifically focusing on innovative cancer therapies - Technology: INT230-6 combines sodium hydroxybenzoyl amlodipine (SHAU) with cisplatin and vinblastine, designed to enhance drug delivery and immune response within tumors [5][6][8] Core Points and Arguments 1. Clinical Study Overview: The IT01 study evaluated INT230-6 in metastatic refractory patients with solid tumors, highlighting a novel approach to intratumoral chemotherapy [10][11] 2. Dosing Strategy: Dosing was personalized based on tumor size, with a maximum of 175 milliliters administered safely [11][12] 3. Safety Profile: INT230-6 demonstrated a favorable safety profile with no dose-limiting toxicities reported, and most adverse events were mild [16][17] 4. Efficacy Results: - Disease control rate was 75% for monotherapy, with 83% for patients receiving 40% or more of their tumor burden injected [18][19] - Median overall survival was approximately 12 months, significantly higher than the historical average of 4 to 7 months for similar treatments [22][23] 5. Immune Response: The treatment induced infiltration of activated immune cells in the tumor microenvironment, suggesting a systemic anti-tumor effect [30][31] 6. Study Limitations: The study was not randomized and had a limited patient number, which may affect the generalizability of the results [31] Additional Important Information - Future Steps: The company is seeking approximately $25 million in funding to restart a paused Phase 3 trial, which has already received regulatory approval in eight countries [40][42] - Combination Studies: There are ongoing studies combining INT230-6 with immunotherapy agents, although results from these cohorts were not included in the current publication [45][46] - Patient Demographics: The study included a diverse range of solid tumor types, with sarcoma being the most common [14][25] Conclusion - INT230-6 shows promise as a novel treatment for solid tumors, with a favorable safety profile and encouraging efficacy results. The company is actively seeking funding to advance its clinical trials and further explore the potential of this innovative therapy.